Search

Your search keyword '"Escudier, Bernard"' showing total 37 results
Start Over Author "Escudier, Bernard" Publisher wiley
37 results on '"Escudier, Bernard"'

1. Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

Author

Colomba, Emeline, primary, Alves Costa Silva, Carolina, additional, Le Teuff, Gwénaël, additional, Elmawieh, Jamie, additional, Afonso, Daniel, additional, Benchimol‐Zouari, Axelle, additional, Guida, Annalisa, additional, Derosa, Lisa, additional, Flippot, Ronan, additional, Raynard, Bruno, additional, Escudier, Bernard, additional, Bidault, François, additional, and Albiges, Laurence, additional

Published
2022
Full Text
View/download PDF

2. Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Author

Motzer, Robert J., primary, McDermott, David F., additional, Escudier, Bernard, additional, Burotto, Mauricio, additional, Choueiri, Toni K., additional, Hammers, Hans J., additional, Barthélémy, Philippe, additional, Plimack, Elizabeth R., additional, Porta, Camillo, additional, George, Saby, additional, Powles, Thomas, additional, Donskov, Frede, additional, Gurney, Howard, additional, Kollmannsberger, Christian K., additional, Grimm, Marc‐Oliver, additional, Barrios, Carlos, additional, Tomita, Yoshihiko, additional, Castellano, Daniel, additional, Grünwald, Viktor, additional, Rini, Brian I., additional, McHenry, M. Brent, additional, Lee, Chung‐Wei, additional, McCarthy, Jennifer, additional, Ejzykowicz, Flavia, additional, and Tannir, Nizar M., additional

Published
2022
Full Text
View/download PDF

3. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

Author

Motzer, Robert J., primary, Escudier, Bernard, additional, George, Saby, additional, Hammers, Hans J., additional, Srinivas, Sandhya, additional, Tykodi, Scott S., additional, Sosman, Jeffrey A., additional, Plimack, Elizabeth R., additional, Procopio, Giuseppe, additional, McDermott, David F., additional, Castellano, Daniel, additional, Choueiri, Toni K., additional, Donskov, Frede, additional, Gurney, Howard, additional, Oudard, Stéphane, additional, Richardet, Martin, additional, Peltola, Katriina, additional, Alva, Ajjai S., additional, Carducci, Michael, additional, Wagstaff, John, additional, Chevreau, Christine, additional, Fukasawa, Satoshi, additional, Tomita, Yoshihiko, additional, Gauler, Thomas C., additional, Kollmannsberger, Christian K., additional, Schutz, Fabio A., additional, Larkin, James, additional, Cella, David, additional, McHenry, M. Brent, additional, Saggi, Shruti Shally, additional, and Tannir, Nizar M., additional

Published
2020
Full Text
View/download PDF

4. Patient‐reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma

Author

Pal, Sumanta K., primary, McDermott, David F., additional, Atkins, Michael B., additional, Escudier, Bernard, additional, Rini, Brian I., additional, Motzer, Robert J., additional, Fong, Lawrence, additional, Joseph, Richard W., additional, Oudard, Stephane, additional, Ravaud, Alain, additional, Bracarda, Sergio, additional, Suárez, Cristina, additional, Lam, Elaine T., additional, Choueiri, Toni K., additional, Ding, Beiying, additional, Quach, Caroleen, additional, Hashimoto, Kenji, additional, Schiff, Christina, additional, Piault‐Louis, Elisabeth, additional, and Powles, Thomas, additional

Published
2020
Full Text
View/download PDF

5. Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study

Author

Lebacle, Cedric, primary, Bensalah, Karim, additional, Bernhard, Jean-Christophe, additional, Albiges, Laurence, additional, Laguerre, Brigitte, additional, Gross-Goupil, Marine, additional, Baumert, Herve, additional, Lang, Herve, additional, Tricard, Thibault, additional, Duclos, Brigitte, additional, Arnoux, Armelle, additional, Piedvache, Celine, additional, Patard, Jean-Jacques, additional, and Escudier, Bernard, additional

Published
2018
Full Text
View/download PDF

7. Local recurrence after radical nephrectomy for kidney cancer: management and prediction of outcomes. a multi‐institutional study

Author

Paparel, Philippe, primary, Bigot, Pierre, additional, Matillon, Xavier, additional, Bensalah, Karim, additional, Salomon, Laurent, additional, Baumert, Hervé, additional, Bastide, Cyril, additional, Thuret, Rodolphe, additional, Karsenty, Gilles, additional, Long, Jean Alexandre, additional, Ammi, Myriam, additional, Bessede, Thomas, additional, Bin, Sylvie, additional, Roux, Adeline, additional, Escudier, Bernard, additional, Rioux Leclercq, Nathalie, additional, Pignot, Géraldine, additional, Soulie, Michel, additional, and Patard, Jean‐Jacques, additional

Published
2013
Full Text
View/download PDF

13. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney

Author

Rini, Brian, primary, Szczylik, Cezary, additional, Tannir, Nizar M., additional, Koralewski, Piotr, additional, Tomczak, Piotr, additional, Deptala, Andrzej, additional, Dirix, Luc Y., additional, Fishman, Mayer, additional, Ramlau, Rodryg, additional, Ravaud, Alain, additional, Rogowski, Wojciech, additional, Kracht, Karolyn, additional, Sun, Yu-Nien, additional, Bass, Michael B., additional, Puhlmann, Markus, additional, and Escudier, Bernard, additional

Published
2012
Full Text
View/download PDF

16. Sunitinib rechallenge in metastatic renal cell carcinoma patients

Author

Zama, Ivan N., primary, Hutson, Thomas E., additional, Elson, Paul, additional, Cleary, James M., additional, Choueiri, Toni K., additional, Heng, Daniel Y.C., additional, Ramaiya, Nikhil, additional, Michaelson, M. Dror, additional, Garcia, Jorge A., additional, Knox, Jennifer J., additional, Escudier, Bernard, additional, and Rini, Brian I., additional

Published
2010
Full Text
View/download PDF

17. Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

Author

Bracarda, Sergio, primary, Bellmunt, Joaquim, additional, Melichar, Bohuslav, additional, Négrier, Sylvie, additional, Bajetta, Emilio, additional, Ravaud, Alain, additional, Sneller, Vesna, additional, and Escudier, Bernard, additional

Published
2010
Full Text
View/download PDF

18. Phase 3 trial of everolimus for metastatic renal cell carcinoma

Author

Motzer, Robert J., primary, Escudier, Bernard, additional, Oudard, Stephane, additional, Hutson, Thomas E., additional, Porta, Camillo, additional, Bracarda, Sergio, additional, Grünwald, Viktor, additional, Thompson, John A., additional, Figlin, Robert A., additional, Hollaender, Norbert, additional, Kay, Andrea, additional, and Ravaud, Alain, additional

Published
2010
Full Text
View/download PDF

19. Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference

Author

Atkins, Michael B., primary, Bukowski, Ronald M., additional, Escudier, Bernard J., additional, Figlin, Robert A., additional, Hudes, Gary H., additional, Kaelin, William G., additional, Linehan, W. Marston, additional, McDermott, David F., additional, Mier, James W., additional, Pedrosa, Ivan, additional, Rini, Brian I., additional, Signoretti, Sabina, additional, Sosman, Jeffrey A., additional, Teh, Bin Tean, additional, Wood, Christopher G., additional, Zurita, Amado J., additional, and King, Laura, additional

Published
2009
Full Text
View/download PDF

21. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

Author

Kruit, Wim H.J., primary, van Ojik, Heidi H., additional, Brichard, Vincent G., additional, Escudier, Bernard, additional, Dorval, Thierry, additional, Dréno, Brigitte, additional, Patel, Poulam, additional, van Baren, Nicolas, additional, Avril, Marie-Françoise, additional, Piperno, Sophie, additional, Khammari, Amir, additional, Stas, Marguerite, additional, Ritter, Gerd, additional, Lethé, Bernard, additional, Godelaine, Danièle, additional, Brasseur, Francis, additional, Zhang, Yi, additional, van der Bruggen, Pierre, additional, Boon, Thierry, additional, Eggermont, Alexander M.M., additional, and Marchand, Marie, additional

Published
2005
Full Text
View/download PDF

24. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-?-2a in patients with metastatic melanoma

Author

Dorval, Thierry, primary, N�grier, Sylvie, additional, Chevreau, Christine, additional, Avril, Marie-Fran�oise, additional, Baume, Daniel, additional, Cupissol, Didier, additional, Oskam, Ralph, additional, de Peuter, Ria, additional, Vinke, Jan, additional, Herrera, Alain, additional, and Escudier, Bernard, additional

Published
1999
Full Text
View/download PDF

26. Overrepresentation of 7q31 and 17q in renal cell carcinomas

Author

Glukhova, Liubov, primary, Goguel, Anne-Françoise, additional, Chudoba, Ilse, additional, Angevin, Eric, additional, Pavon, Christine, additional, Terrier-Lacombe, Marie-José, additional, Meddeb, Mounira, additional, Escudier, Bernard, additional, and Bernheim, Alain, additional

Published
1998
Full Text
View/download PDF

35. Progression-free survival as a surrogate endpoint of overall survival in patients with metastatic renal cell carcinoma.

Author

Halabi S, Rini B, Escudier B, Stadler WM, and Small EJ

Subjects
Aged, Antibodies, Monoclonal, Humanized administration & dosage, Bevacizumab, Clinical Trials, Phase III as Topic methods, Disease-Free Survival, Endpoint Determination, Female, Humans, Interferon-alpha administration & dosage, Male, Middle Aged, Multivariate Analysis, Neoplasm Metastasis, Proportional Hazards Models, Prospective Studies, Randomized Controlled Trials as Topic, Survival Analysis, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Renal Cell drug therapy, Interferon-alpha therapeutic use, Kidney Neoplasms drug therapy
Abstract

Background: The current study was conducted to investigate the dependence between progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC) and to explore whether PFS can be used as an intermediate endpoint of OS in this patient population., Methods: A total of 1381 patients from 2 prospective phase 3 trials (Cancer and Leukemia Group B [CALGB] 90206 and AVOREN) of interferon-alpha with or without bevacizumab were analyzed. Both trials recruited previously untreated patients with clear cell mRCC with an Eastern Cooperative Oncology Group performance status of 0 to 2; adequate bone marrow, hepatic, cardiac, and renal function; and controlled blood pressure. The CALGB study served as the training data set, and the AVOREN study served as the testing data set. The dependence between PFS and OS was investigated using the Kendall tau for bivariate time-to-event endpoints., Results: In the training data set, the median OS times among patients who experienced progressive disease at 3 months or 6 months were 6 months and 8 months, respectively, compared with 25 months and 30 months, respectively, (P < .001) in patients who did not develop disease progress. The adjusted hazard ratios (HR) were 2.6 (P < .0001) and 2.8 (P < .0001), respectively, for patients who did and did not progress at 3 months or 6 months. The dependence between PFS and OS was 0.53. These associations were confirmed in the testing data set., Conclusions: In patients with mRCC who were treated with interferon-alpha with or without bevacizumab, the PFS at 3 months and 6 months was found to be predictive of OS. A high dependence between PFS and OS was observed, suggesting that PFS may be used as a surrogate endpoint for OS. Although this is a novel observation for RCC, these findings require validation in patients with mRCC who are treated with other targeted agents., (© 2013 American Cancer Society.)

Published
2014
Full Text
View/download PDF

36. Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome.

Author

Sadeghi S, Albiges L, Wood LS, Black SL, Gilligan TD, Dreicer R, Garcia JA, Escudier BJ, and Rini BI

Subjects
Aged, Aged, 80 and over, Carcinoma, Renal Cell secondary, Disease-Free Survival, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Time Factors, Antineoplastic Agents therapeutic use, Carcinoma, Renal Cell drug therapy, Kidney Neoplasms drug therapy, Vascular Endothelial Growth Factor A antagonists & inhibitors, Withholding Treatment
Abstract

Background: The current treatment of metastatic renal cell carcinoma (mRCC) with vascular endothelial growth factor (VEGF)-targeted agents is continuous therapy until progression of disease (PD) or unacceptable toxicity. Chronic mild to moderate toxicity and risk of long-term toxicity ensue for some patients. It is hypothesized that patients with an initial response to treatment can maintain disease control off all therapy for a period of time., Methods: A retrospective study of patients with mRCC who initiated VEGF-targeted therapy between January 2004 and December 2009 at The Cleveland Clinic Foundation, Cleveland, Ohio, or Institut Gustave-Roussy, Villejuif, France, was conducted. Patients had achieved RECIST (Response Evaluation Criteria in Solid Tumors)-defined stable disease or better on therapy, and were then taken off all therapy for reasons not including disease progression. Patient, disease, and therapy characteristics were recorded. The primary objective was progression-free survival (PFS), measured as the time from discontinuation of therapy to RECIST-defined PD., Results: Forty patients were identified. After a median follow-up of 29.7 months (range, 4.2 to 84.7 months), 25 patients (63%) had PD off therapy (median PFS, 10.0 months; range, 1.4-27.2 months). Among these patients, 8 (32%) had progression in sites that were not previously involved with disease. Heng risk group (hazard ratio, 2.49; 95% confidence interval, 1.19-5.22; P = .011) and achievement of a complete response prior to discontinuing therapy (hazard ratio, 0.20; 95% confidence interval, 0.04-0.86; P = .025) were independent predictors of PFS in a multivariable Cox proportional hazards model., Conclusions: A select subset of mRCC patients achieving stable disease or better on VEGF-targeted therapy can be observed off all therapy. Further prospective investigation is warranted., (Copyright © 2011 American Cancer Society.)

Published
2012
Full Text
View/download PDF

37. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial.

Author

Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, and Escudier B

Subjects
Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Disease-Free Survival, Female, Humans, Interferon alpha-2, Male, Middle Aged, Neoplasm Metastasis, Prognosis, Quality of Life, Recombinant Proteins, Survival Rate, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Renal Cell drug therapy, Interferon-alpha administration & dosage, Interleukin-2 administration & dosage, Kidney Neoplasms drug therapy, Medroxyprogesterone administration & dosage
Abstract

Background: Few randomized trials have compared the survival benefit of interferon-alfa over controls in metastatic renal cell carcinoma, and none has been performed using interleukin-2. The Programme Etude Rein Cytokines (PERCY) Quattro trial was designed to evaluate both cytokines for their survival benefit to intermediate prognosis patients, who represent the majority of candidates for these treatments., Methods: Patients were randomized in a 2-by-2 factorial design to medroxyprogesterone acetate 200 mg daily, interferon-alfa 9 million IU 3 times a week, subcutaneous interleukin-2 9 million IU daily, or a combination of both cytokines. Tumor response was evaluated at Week 12 and Month 6; progression-free patients received further identical treatment for a maximum of 3 additional months. Primary endpoint was overall survival; secondary endpoints were disease-free survival, response rate, toxicity, and quality of life. Survival was analyzed on an intent-to-treat basis., Results: From January 2000 to July 2004, 492 patients were enrolled. Analysis was performed after a 29.2-month median follow-up (range, 0 months to 54.6 months). There were no significant survival differences between the 244 interferon-alfa-treated patients and 248 noninterferon-alfa patients (hazard ratio, 1.00; 95% CI, 0.81-1.24) or between the 247 interleukin-2 and 245 noninterleukin-2-treated patients (hazard ratio, 1.07; 95% CI, 0.87-1.33; log rank, 0.99 and 0.52, respectively). Grade 3-4 toxicities were significantly more frequent in cytokine-treated patients than in medroxyprogesterone-treated patients., Conclusions: Subcutaneous interleukin-2 and/or interferon-alfa provide no survival benefit in metastatic renal cancers of intermediate prognosis, and they induce a significant risk of toxicity. Newly available angiogenesis inhibitors should be preferred for these patients., (Copyright (c) 2007 American Cancer Society.)

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results